CA-MOBILEIRON
8.5.2019 15:02:09 CEST | Business Wire | Press release
MobileIron (NASDAQ:MOBL) introduces the industry’s first mobile-centric, zero trust security platform. MobileIron's mobile-centric strategy allows for continuous enforcement and protection of data, both on the device and on the network, with comprehensive correlation between the critical signals for zero trust: user, device, apps, networks, and threats. This makes the world’s most ubiquitous product – the mobile device – your ID and secure access to the enterprise. This platform goes beyond identity management and gateway approaches by utilizing a more comprehensive set of attributes before granting access.
With mobile devices as your ID, organizations replace the password with a secure and frictionless alternative, ushering in a new era of user authentication. MobileIron is introducing a revolutionary zero sign-on experience built on the company’s leading unified endpoint management (UEM) platform and powered by the MobileIron Access solution.
Zero sign-on completely eliminates passwords as the method for user authentication, replacing single sign-on, which still requires at least one username and password. MobileIron paved the way for a zero sign-on enterprise with its Access product in 2017, which enabled zero sign-on to cloud services on managed devices. Today’s announcement extends this capability, making passwordless access to cloud services available from any device, managed or unmanaged, using the mobile device as the user’s secure ID.
“Mobile is the center of our universe, both personally and professionally. With that comes a need for a mobile-centric enterprise-grade security solution,” said Simon Biddiscombe, CEO, MobileIron. “We are delivering that solution – making the mobile device your ID and access to the enterprise. And we didn’t stop there. We are eliminating passwords for any device, whether managed or unmanaged, because we think single sign-on is one sign-on too many.”
Zero sign-on solves three problems inherent in passwords. As Forrester Research analysts Andras Cser and Merritt Maxim explain: “First, passwords represent a security risk because they can be easily hacked, and password reuse can start an avalanche of breaches. Second, password-related reset costs generate significant operational support costs. Third, password authentication is often the source of a bad user experience, especially in mobile environments” (Forrester: Understand The State Of Identity And Access Management, 2018 To 2019 ) . Zero sign-on eliminates the pain and expense of traditional user credentials, replacing it with a seamless, secure authentication alternative.
A passwordless enterprise has been an unfulfilled promise for years. In fact, according to an April 2019 IDG survey of security decision makers, 86% would do away with passwords if they could. The same survey found that nearly 9 out of 10 security leaders believe that, in the near future, mobile devices will serve as the digital ID to access enterprise services and data.
The MobileIron security platform is built on the foundation of award-winning and industry-leading unified endpoint management (UEM) capabilities with additional zero trust-enabling technologies, including zero sign-on (ZSO), multi-factor authentication (MFA), and mobile threat defense (MTD). Together, they enable a seamless, secure user experience by ensuring only authorized users, devices, apps, and services can access business resources.
MobileIron’s vision is to revolutionize enterprise authentication with a mobile ID and zero sign-on experience from any device, any OS, any location, to any service. Turning vision into reality, MobileIron’s zero sign-on for unmanaged devices will be available in June 2019 on iOS devices. These capabilities will extend to Android devices later this year. For more information, visit here .
About MobileIron
MobileIron is redefining enterprise security with the industry’s first mobile-centric, zero trust platform built on the foundation of unified endpoint management (UEM) to secure access and protect data across the perimeter-less enterprise. Over 17,000 customers, including the world’s largest financial institutions, intelligence agencies, and other highly regulated companies rely on MobileIron to enable a seamless and secure user experience by ensuring only authorized users, devices, apps, and services can access business resources. For more information, visit www.mobileiron.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005145/en/
Contact:
Marjaneh Ravai MobileIron mravai@mobileiron.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
